ACVA ACV Auctions Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ACVA Stock | Fundamental Analysis & Investment Insights
NYSE
Consumer Cyclical
Auto & Truck Dealerships
Current Price
Live
$8.5
Analyst Target
$10.71
+26.0%
Upside
52W High
$22.09
52W Low
$4.95
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$1.54B
P/E
N/A
ROE
-16.3%
Profit margin
-9.9%
Debt/Equity
0.61
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
68%
Analysis Accuracy
ACVA exhibits a Piotroski F-Score of 5/9, indicating stable financial health, but lacks an Altman Z-Score, limiting distress risk assessment. The company shows strong revenue growth (16.5% YoY) and impressive earnings surprise trends, yet remains unprofitable with negative profit and return metrics. Valuation appears stretched on a forward P/E of 34.17 despite weak fundamentals, while insider selling and mixed technicals suggest caution. Analysts recommend a 'buy' with a $10.71 target, implying upside, but fundamentals do not robustly support this optimism.
Key Strengths
Revenue growth of 16.5% YoY outpaces sector average of 6.8%
Consistent earnings beat streak: 3 out of last 4 quarters exceeded estimates
High average earnings surprise of 50.71% over recent quarters
Strong gross margin of 28.98% despite operating losses
Low debt/equity ratio of 0.61, below sector average of 1.61
Key Risks
Piotroski F-Score of 5 indicates borderline financial health, not strong
Persistent unprofitability: negative net margin (-9.89%) and ROE (-16.33%)
No Altman Z-Score available, creating uncertainty around bankruptcy risk
Insider selling activity: $0.08M in sales over last 6 months, no buys
Stock trades at high forward P/E of 34.17 despite negative earnings history
AI Fair Value Estimate
Based on comprehensive analysis
$10.71
+26.0% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
45
Moderate
45
70
52
56
0
AI Verdict
Cautiously optimistic with significant risks
Key drivers: Revenue growth and earnings surprise momentum, Low leverage relative to peers, High forward valuation despite weak profitability, Negative ROE and inconsistent earnings, Analyst optimism vs insider skepticism
Confidence
70%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 2.10 is below sector P/E average contextually
Watchpoints
- Forward P/E of 34.17 is high for a company with negative historical earnings
- No Graham Number or Intrinsic Value provided, limiting value assessment
- Price/Book of 3.37 elevated given negative ROE
Future
70/100
Ref Growth rates
Positives
- 16.5% YoY revenue growth well above sector average
- Most recent YoY EPS growth of +40.0% and Q/Q EPS surge of +275.0%
- Analyst target implies 25.9% upside to $10.71
Watchpoints
- Earnings growth not consistently positive; relies on recent turnarounds
Past
52/100
Ref Historical trends
Positives
- Improving earnings trajectory from heavy losses to near-breakeven
- History of beating earnings estimates, especially since 2023
Watchpoints
- 5-Year price return down 72.8%, underperforming significantly
- Multiple quarters with negative EPS and shrinking surprises in early 2022
Health
56/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 5/9 indicates stable, not weak, financial condition
- Current ratio (1.62) and quick ratio (1.55) suggest adequate short-term liquidity
- Debt/equity of 0.61 is conservative compared to sector average
Watchpoints
- No Altman Z-Score available, raising red flag
- ROA of -2.87% and ROE of -16.33% indicate poor asset and equity efficiency
- Operating margin negative at -2.51%
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid; Dividend Strength score of 0/100
- No yield, payout, or history to assess
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.5
Analyst Target
$10.71
Upside/Downside
+26.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACVA and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACVA
ACV Auctions Inc.
Primary
|
-72.8% | -8.0% | -61.5% | -41.7% | +2.9% | -2.8% |
|
BH-A
Biglari Holdings Inc.
Peer
|
+361.4% | +231.2% | +131.1% | +55.9% | +29.8% | +2.3% |
|
ARHS
Arhaus, Inc.
Peer
|
-16.2% | -22.5% | -15.4% | +8.7% | -11.4% | -4.2% |
|
BH
Biglari Holdings Inc.
Peer
|
+310.2% | +205.9% | +110.4% | +46.2% | +29.3% | +1.5% |
|
ARCO
Arcos Dorados Holdings Inc.
Peer
|
+60.4% | -5.4% | +11.6% | +9.9% | +6.1% | +3.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
34.17
PEG Ratio
N/A
P/B Ratio
3.37
P/S Ratio
2.1
EV/Revenue
1.92
EV/EBITDA
-48.37
Market Cap
$1.54B
Profitability
Profit margins and return metrics
Profit Margin
-9.89%
Operating Margin
-2.51%
Gross Margin
28.98%
ROE
-16.33%
ROA
-2.87%
Growth
Revenue and earnings growth rates
Revenue Growth
+16.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.61
Moderate
Current Ratio
1.62
Good
Quick Ratio
1.55
Excellent
Cash/Share
$1.83
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-18
$N/A
2025-11-05
$0.07
+8.6% surprise
2025-08-11
$-0.04
+34.3% surprise
2025-05-07
$0.04
+109.2% surprise
Consumer Cyclical Sector Comparison
Comparing ACVA against 94 companies in the Consumer Cyclical sector
(6 bullish, 49 neutral, 39 bearish)
Return on Equity (ROE)
-16.33%
This Stock
vs
6.28%
Sector Avg
-360.2%
(Below Avg)
Profit Margin
-9.89%
This Stock
vs
0.87%
Sector Avg
-1234.6%
(Weaker)
Debt to Equity
0.61
This Stock
vs
1.65
Sector Avg
-63.1%
(Less Debt)
Revenue Growth
16.5%
This Stock
vs
7.63%
Sector Avg
+116.4%
(Fast Growth)
Current Ratio
1.62
This Stock
vs
1.86
Sector Avg
-13.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACVA
ACV Auctions Inc.
|
NEUTRAL | $1.54B | - | -16.3% | -9.9% | $8.5 | |
|
BH-A
Biglari Holdings Inc.
|
BEARISH | $1.51B | 227.28 | 0.4% | 0.5% | $2434.13 | |
|
ARHS
Arhaus, Inc.
|
NEUTRAL | $1.46B | 20.72 | 20.4% | 5.4% | $10.36 | |
|
BH
Biglari Holdings Inc.
|
BEARISH | $1.46B | 217.27 | 0.4% | 0.5% | $467.14 | |
|
ARCO
Arcos Dorados Holdings Inc.
|
NEUTRAL | $1.64B | 6.71 | 39.0% | 5.4% | $7.78 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-15 | PEER ANDREW | Officer | Option Exercise | 1,750 | $4,270 |
| 2026-01-15 | PEER ANDREW | Officer | Sale | 1,750 | $15,488 |
| 2026-01-12 | CHAMOUN GEORGE G | Chief Executive Officer | Purchase | 14,286 | $125,860 |
| 2025-12-31 | PEER ANDREW | Officer | Stock Award | 19,431 | - |
| 2025-12-15 | CHAMOUN GEORGE G | Chief Executive Officer | Purchase | 31,172 | $248,441 |
| 2025-12-15 | PEER ANDREW | Officer | Option Exercise | 1,750 | $4,270 |
| 2025-12-15 | PEER ANDREW | Officer | Sale | 1,750 | $14,052 |
| 2025-12-01 | PEER ANDREW | Officer | Option Exercise | 1,750 | $3,500 |
| 2025-12-01 | PEER ANDREW | Officer | Sale | 1,750 | $14,000 |
| 2025-11-17 | CASTILLO KIRSTEN M | Director | Purchase | 20,000 | $125,250 |
| 2025-11-14 | HIRSCH BRIAN | Director | Purchase | 80,571 | $500,346 |
| 2025-11-10 | GOODMAN ROBERT P | Director | Purchase | 912,408 | $5,118,609 |
| 2025-10-15 | PEER ANDREW | Officer | Option Exercise | 1,750 | $3,500 |
| 2025-10-15 | PEER ANDREW | Officer | Sale | 1,750 | $15,470 |
| 2025-09-15 | PEER ANDREW | Officer | Option Exercise | 1,750 | $3,500 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
12 analysts
Barclays
2026-01-21
Equal-Weight
Equal-Weight
Jefferies
2025-12-11
Buy
Hold
Barclays
2025-12-04
Equal-Weight
Equal-Weight
Citigroup
2025-11-21
Buy
Buy
Barclays
2025-11-12
Equal-Weight
Goldman Sachs
2025-11-07
Buy
Buy
JP Morgan
2025-11-06
Overweight
Overweight
Barrington Research
2025-11-06
Outperform
Market Perform
B of A Securities
2025-11-06
Buy
Underperform
Needham
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning ACVA from our newsroom.
Newest → oldest
No matching news yet.